Fact CheckerSign in

NCT06696235RecruitingPhase 4

Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator

AcceleRatEd vs. StandarD ContinUous Renal ReplaCement ThErapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator: Randomized-Controlled Trial

Source: ClinicalTrials.gov · Last updated 5 Jan 2026

Brief summary (registry, in English)

This study was designed to compare the safety and efficacy of early continuous renal replacement therapy with standard continuous renal replacement therapy in the presence of acute kidney injury (stage 2 or greater acute kidney injury according to the KDIGO \[The Kidney Disease: Improving Global Outcomes\] classification) in patients with advanced cardiogenic shock on extracorporeal membrane oxygenation.

Status (registry)
Recruiting
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
408 (estimated)
First submitted
5 Nov 2024
Start date
31 Dec 2024
Primary completion date
31 Dec 2028
Lead sponsor
Samsung Medical Center
NCT number
NCT06696235

What you commit to

  • Study type: Interventional · Phase 4
  • Planned participants: 408
  • From 31 Dec 2024 to the primary completion date, 31 Dec 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Criteria mandating CRRT initiation: acute kidney injury prior to enrollment caused by any reason, at least one of the following criteria is met.
  • Kidney transplant within the past 365 days
  • Other severe concomitant disease with limited life expectancy \< 6 months
  • Presence of a drug overdose or dialyzable toxin that necessitates RRT.

Other illness

  • Unwitnessed out-of-hospital cardiac arrest with persistent Glasgow coma scale \<8 after the return of spontaneous circulation.

Lab values

  • serum potassium \> 6.5 mmol/L
  • serum potassium\> 6.0 mmol/L persisting despite medical treatment.
  • metabolic acidosis (pH \< 7.15 and PaCO2 \< 35 mmHg or serum bicarbonate \< 12 mmol/L)
  • blood urea nitrogen level ≥100 mg/dL.
  • Chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR)\<30 mL/min/1.73m2 or end-stage kidney disease under dialysis

Other

  • Other causes of shock (hypovolemia, sepsis, obstructive shock).
  • diuretics refractory volume overload or pulmonary edema
  • Receipt of any RRT in the preceding 2 months
  • Known heparin intolerance.
  • Pregnancy or breastfeeding
  • Do not resuscitate wish.
  • Presence or strong clinical suspicion of post-renal AKI duet to obstruction, rapidly progressive glomerulonephritis, vasculitis, thrombotic microangiopathy or acute interstitial nephritis
  • Clinical decision by a responsible physician to immediately start RRT.
  • Clinical decision by a responsible physician to defer RRT.

Who the study is looking for

  • The subject must be at least 19 years of age.
  • Patients presented with CS (Society for Cardiovascular Angiography and Interventions \[SCAI\] Shock classification C, D or E) \* who requiring VA-ECMO.
  • Classic CS (Stage C) was defined as the following criteria. A. Systolic blood pressure less than 90 mmHg for more than 30 min or catecholamines required to maintain pressure more than 90 mmHg during systole. B. Sign of pulmonary congestion
  • Sign of impaired organ perfusion with at least one of the following:
  • altered mental status.
  • cold, clammy skin and extremities.
  • oliguria with urine output \< 30ml/h.
  • serum lactate \> 2.0 mmol/l.
    • SCAI Shock classification D is defined as failure to respond to initial interventions with clinical deterioration of classic CS or SCAI Shock classification E is defined as cardiac arrest with ongoing cardiopulmonary resuscitation requiring VA-ECMO
    • Patients in the first 48 hours of CS developing AKI with at least one criterion (Characteristic of the stage 2 AKI according to Kidney Disease: Improving Global Outcomes \[KDIGO\] classification)
    • A 2-fold or over increase in serum creatinine relative to baseline
    • A reduction in urine output of ≤0.5 ml/kg/h for ≥ 12 hours

Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Samsung Medical Center
Coordinator of this site? Confirm its status
SeoulSouth KoreaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.